Depletion of USP37 impairs ccRCC growth in 2D and 3D growth assays and in vivo kidney tumorigenesis and lung metastasis [216]; therefore, inhibiting USP37 could be a viable therapeutic approach in VHL-deficient or HIF-2α-dependent tumors. Here, USP37 is linked to nonpapillary renal cell carcinoma.